These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Decreased tissue plasminogen activator and increased plasminogen activator inhibitors and increased activator protein-1 and specific promoter 1 are associated with inhibition of invasion in human A375 melanoma deprived of tyrosine and phenylalanine. Pelayo BA; Fu YM; Meadows GG Int J Oncol; 2001 Apr; 18(4):877-83. PubMed ID: 11251188 [TBL] [Abstract][Full Text] [Related]
26. [Placenta accreta: epidemiology, molecular mechanism (hypothesis) and some clinical remarks]. Uszyński W; Uszyński M Ginekol Pol; 2004 Dec; 75(12):971-8. PubMed ID: 15751221 [TBL] [Abstract][Full Text] [Related]
27. Plasminogen activators and their inhibitors in arthritic disease. Hamilton JA; Campbell IK; Wojta J; Cheung D Ann N Y Acad Sci; 1992 Dec; 667():87-100. PubMed ID: 1309075 [No Abstract] [Full Text] [Related]
28. Regulation of the pericellular activation of plasminogen and its role in tissue-destructive processes. Vaheri A; Bizik J; Salonen EM; Tapiovaara H; Sirén V; Myöhänen H; Stephens RW Acta Ophthalmol Suppl (1985); 1992; (202):34-41. PubMed ID: 1322009 [No Abstract] [Full Text] [Related]
30. The plasminogen activation system in melanoma cell lines and in melanocytic lesions. de Vries TJ; van Muijen GN; Ruiter DJ Melanoma Res; 1996 Apr; 6(2):79-88. PubMed ID: 8791264 [TBL] [Abstract][Full Text] [Related]